

IMPACT FACTOR 3.4





an Open Access Journal by MDPI

# Personalized Diagnosis and Treatment for Congenital Heart Disease

Guest Editors:

#### Dr. David S. Majdalany

Department of Cardiovascular Medicine, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA

### Dr. Donald J. Hagler

- 1. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA
- 2. Division of Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA

Deadline for manuscript submissions:

20 December 2024

## **Message from the Guest Editors**

Patients with congenital heart disease are surviving into adulthood thanks to advances in diagnosis as well as therapy at an early age. In fact, there are more adults with congenital heart disease than children, with an evergrowing population. Educating and empowering patients as well as their primary care providers and general cardiologists are important for optimizing the patients' longitudinal care. Moreover, recognizing that the interventions patients have undergone, whether surgical or percutaneous, are palliative means that, in most cases, these patients would require lifelong follow-up at a center with adult congenital heart disease expertise. Common long-term issues, depending on the cardiac abnormalities, can include a need for re-intervention, heart failure, arrhythmias, pulmonary hypertension, endocarditis, risk of and risk with pregnancy/risk to thromboembolism, offspring. However, although the guidelines provide general principles of care, each patient may demonstrate unique features of their cardiac abnormalities and their care must be individualized.







IMPACT FACTOR 3.4





an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

# **Message from the Editor-in-Chief**

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous*))

#### **Contact Us**